Evidence map›Paper›PMID 32107504›Full record

ArticlePloS one2020

Evaluation of bacterial proliferation with a microfluidic-based device: Antibiochip.

Valentina Gallo, Alessia Ruiba, Massimo Zanin, Paolo Begnamino, Sabina Ledda, Tiziana Pesce, Giovanni Melioli, Marco Pizzi

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Valentina GalloBiomed & Nanotech Development & Business Unit, ELTEK S.p.A., Casale Monferrato (AL), Italy.
Alessia RuibaPhenomix S.r.l., Genova, Italy.
Massimo ZaninBiomed & Nanotech Development & Business Unit, ELTEK S.p.A., Casale Monferrato (AL), Italy.
Paolo BegnaminoBiomed & Nanotech Development & Business Unit, ELTEK S.p.A., Casale Monferrato (AL), Italy.
Sabina LeddaMicrobiology Section, Laboratorio Albaro S.r.l., Genova, Italy.
Tiziana PesceMicrobiology Section, Laboratorio Albaro S.r.l., Genova, Italy.
Giovanni MelioliPhenomix S.r.l., Genova, Italy.
Marco PizziBiomed & Nanotech Development & Business Unit, ELTEK S.p.A., Casale Monferrato (AL), Italy.ORCID 0000-0002-0985-7321
Humanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The measurement of the proliferation (and the relevant inhibition of proliferation) of microbes is used in different settings, from industry to laboratory medicine. Thus, in this study, the capacity of the Antibiochip (ELTEK spa), a microfluidic-based device, to measure the amount of E. coli in certain culture conditions, was evaluated. An Antibiochip is composed of V-shaped microchannels, and the amount of microparticles (such as microbes) is measured by the surface of the pellet after centrifugation. In the present study, different geometries, volumes and times were analyzed. When the best conditions were identified, serial dilutions of microbial cultures were tested to validate the linearity of the results. Then, with the use of wild E. coli strains isolated from medical samples, the relationship between bacterial susceptibility to antibiotics measured by standard methods and that measured by the Antibiochip was evaluated. In this report, the good quality performances of the methods, their linearity and the capacity to identify susceptible microbial strains after 60 minutes of incubation are shown. These results represent a novel approach for ultrarapid antibiograms in clinics.

Indexed as

Lab-On-A-Chip DevicesAnti-Bacterial AgentsBacteriaCell ProliferationEscherichia coliMicrobial Sensitivity TestsMicrofluidic Analytical TechniquesAnti-Bacterial Agents

Identifiers

PMID32107504
PMCPMC7046301
OpenAlexW3008005311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.